Skip to content

The Effct of Chitooligosaccharide on Immune Function in Healthy Adults

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00468962
Enrollment
Unknown
Registered
2007-05-03
Start date
Unknown
Completion date
Unknown
Last updated
2007-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunity

Brief summary

Functional properties of chitooligosaccharides have been studied for antitumor activity, immunostimulating effects, antimicrobial activity, free radical scavening activity, adn angiotensin I converting enzyme inhibitory activity. Recent in vitro, and in vivo toxicity and absorbability studies have demonstrated that chitooligosaccharides have high absorbability and are essentially non-toxic. In the present study, we prepared a chitooligosaccharide with high absorbability and evaluated its effects on activation of immune function and cardiovascular funciton(lipid, atrial stiffness, etc) in healthy adults. This study was a 8-week, randomized, double-blind clinical trial. The 30 volunteers were divided into a control group(n=10), half dose chitooligosaccaride(FACOSTM) intake group(n=10), and full dose FACOS intake group(n=10). Peripheral blood mononuclear cells(PBMCs) were isolated and cultured in 12 well plate for 48 hours. Cytokine production by PBMCs pre- and postintervention were measured simultaneously after stimulation with lipopolysaccaride.

Interventions

DRUGFACOS (functional food)

Sponsors

Eulji University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years

Inclusion criteria

* healthy adults(the ages between 20\ 50 year)

Exclusion criteria

* food allergy and allergy skin disease * severe liver and kidney disease * pregnant, lactating women * cancer, stroke, etc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026